Key HighlightsShares of Tempus AI surged by as much as 10.67% to reach $64.63 following a Piper Sandler upgrade to Overweight with a $76 price objective.The analyst firm cited positive developments from the Personalis acquisition and favorable clinical trial results as reasons for the bullish stance.The company exceeded Q2 expectations with an adjusted loss of $0.04 per share compared to the anticipated $0.14 loss, while revenue climbed 21.6% year-over-year to $382.49 million.Recent catalysts include a $9.5 million federal funding award for AI-driven cardiology research and the launch of an extensive whole-genome database project.Wall Street’s consensus rating stands at Hold with an average price objective of $69.33, although multiple analysts have recently increased their targets.Tempus AI (TEM) shares experienced a notable rally on September 15, advancing as much as 10.67% to trade at $64.63 during intraday action, compared to the previous session’s close of $62.21. The stock touched an intraday peak of $65.50.Tempus AI, Inc., TEMThe primary catalyst behind the surge was an analyst upgrade from Piper Sandler, which elevated TEM to an Overweight rating and established a $76 price objective. The firm cited enthusiasm surrounding Tempus’s strategic acquisition of Personalis along with encouraging clinical trial outcomes as primary factors supporting the upgrade.Chief Executive Eric Lefkofsky reinforced the optimistic outlook at a recent industry conference, emphasizing potential revenue gains from increased pricing on the company’s liquid biopsy product offerings.Strong Quarterly Results Fuel Investor ConfidenceTempus delivered quarterly financial results that exceeded Wall Street forecasts. The healthcare technology firm posted an adjusted per-share loss of $0.04, significantly better than the analyst consensus expectation of a $0.14 loss.Quarterly revenue totaled $382.49 million, marginally surpassing the projected $379.69 million. This figure marked a 21.6% increase compared to the corresponding quarter in the prior year.While the company demonstrated robust revenue expansion, profitability remains elusive. Tempus recorded a net margin of negative 17.77% alongside a return on equity of negative 50.28%.New Growth Drivers EmergeIn addition to the analyst upgrade, market participants are monitoring two significant recent developments. Tempus secured a $9.5 million federal grant designated for advancing its artificial intelligence capabilities in cardiology applications.The organization also unveiled a comprehensive whole-genome dataset initiative designed to broaden its AI-powered diagnostic tools and enhance its data infrastructure. These strategic initiatives underscore Tempus’s commitment to expanding partnerships with healthcare providers and biopharmaceutical companies.Guggenheim increased its price target from $60 to $65 while maintaining a Buy recommendation. Needham reaffirmed its Buy rating with a $75 price objective. HC Wainwright elevated its target from $56 to $66.The overall Wall Street consensus rating remains at Hold, with an average price target of $69.33 based on coverage from 21 analysts. The breakdown includes 11 Buy ratings, eight Hold ratings, and two Sell ratings.Institutional ownership has been expanding steadily. Sumitomo Mitsui Trust Group increased its holdings by 23.4% during the first quarter, while Franklin Resources boosted its position by 27.9% in the fourth quarter. Institutional investors collectively control 24.22% of outstanding shares.Regarding insider activity, EVP Andrew Polovin divested 7,927 shares at $56.00 on August 19, and CEO Ryan Fukushima sold 14,286 shares at $70.00 on August 21. Throughout the past 90 days, company insiders have sold approximately $56.96 million worth of stock.The stock’s 50-day moving average is positioned at $55.99, while the 200-day moving average sits at $52.33. TEM exhibits a debt-to-equity ratio of 3.06 and a beta of 3.72, indicating substantial volatility characteristics.As of September 15, Tempus’s market capitalization stands at approximately $10.65 billion.The post Tempus AI (TEM) Stock Surges 11% on Piper Sandler Upgrade and Federal Grant News appeared first on Blockonomi.